Governance
Axplora has two governance bodies:
Find out more about our commitment to Compliance & Ethics as well as our environmental, social & governance (ESG) initiatives:
Executive committee
The executive committee consists of eight members. The members represent diverse cultural and geographical backgrounds, coming from Germany, India, Italy, Switzerland, Spain, and England.
Find out more about our executive members from their biographies.
Scientific Advisory Board
Our Scientific Advisory Board (SAB) brings together leading international experts with complementary areas of expertise, spanning from catalysis, electrochemistry, steroids to biochemistry and ADCs. They play a key role in following market trends and shaping our R&D activities, focusing on deployment support of Axplora’s innovative technologies and modalities.
The SAB members: Dr. David Cantillo, Prof. Alois Fürstner, Prof. Kerry Chester, Prof. John Woodley, Dr. Michael Reschke.
Find out more about our Scientific Advisory Board.
Compliance & Ethics
At Axplora, we provide the world with a sustainable supply of pharmaceutical ingredients and chemical products, enabling our customers to improve their patients’ quality of life. Our unwavering commitment to business integrity is the cornerstone of this success, as expressed in our Code of Business Conduct and Supplier Code of Conduct.
Environment, social and governance (ESG)
Environment, social, and corporate governance initiatives are essential to our company’s strategy. The ESG roadmap is based on five pillars:
- Health and Safety
- Climate Change
- Energy Management
- Waste Management
- Diversity & Inclusion
Our latest Greenhouse Gases (GHG) report from 2023 shows significant progress in reducing emissions across our operations through innovative solutions and the daily dedicated efforts by our teams.
-9%
absolute greenhouses gases emissions in 2023
-6%
reduction in emissions per million euros of sales in 2023
60%
renewable electricity consumption in Axplora Group